Sun Pharmaceutical Industries Dividends and Buybacks
Dividend criteria checks 4/6
Sun Pharmaceutical Industries is a dividend paying company with a current yield of 0.95% that is well covered by earnings. Next payment date is on 8th August, 2025 with an ex-dividend date of 7th July, 2025.
Key information
0.9%
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | 1.1% |
| Dividend Growth | 19.3% |
| Next dividend pay date | 08 Aug 25 |
| Ex dividend date | 07 Jul 25 |
| Dividend per share | n/a |
| Payout ratio | 35% |
Recent dividend and buyback updates
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50
May 25
Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 04Recent updates
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50
May 25Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching
May 15Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Shares May Have Run Too Fast Too Soon
Feb 23Analysts Are Updating Their Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Estimates After Its Third-Quarter Results
Feb 05Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 04Here's Why Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has Caught The Eye Of Investors
Jan 29Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Robust Product Pipeline And Market Expansion Drive Growth Amidst Challenges
U.S. and India sales, driven by market leadership and product launches, enhance revenue growth and net margins via economies of scale.Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: SUNPHARMA's dividend payments have been volatile in the past 10 years.
Growing Dividend: SUNPHARMA's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Sun Pharmaceutical Industries Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (SUNPHARMA) | 0.9% |
| Market Bottom 25% (IN) | 0.3% |
| Market Top 25% (IN) | 1.2% |
| Industry Average (Pharmaceuticals) | 0.8% |
| Analyst forecast (SUNPHARMA) (up to 3 years) | 1.1% |
Notable Dividend: SUNPHARMA's dividend (0.95%) is higher than the bottom 25% of dividend payers in the Indian market (0.27%).
High Dividend: SUNPHARMA's dividend (0.95%) is low compared to the top 25% of dividend payers in the Indian market (1.19%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (35.1%), SUNPHARMA's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (32.1%), SUNPHARMA's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/12 00:34 |
| End of Day Share Price | 2025/06/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sun Pharmaceutical Industries Limited is covered by 74 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |